Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The Immune System and Advocacy

Philippe A. Saxe, MD  |  Issue: February 2011  |  February 12, 2011

Many physicians are understandably pessimistic about finding solutions to these complicated issues, and others seem resigned to the fact that they are helpless to change things for the better. A favorable outcome for physicians is not assured, even if we fight the fight. However, the outcome if we chose to be complacent and let others fight our fight is assured!

Physicians must educate themselves regarding these and other issues that are threatening their livelihood. We can enlist lobbyists and work in a concerted effort through our state and national societies, the ACR, the Coalition of State Rheumatology Organizations, and even lay organizations to effect change. States without societies should be encouraged and assisted to adopt one. At the local level, physicians should identify local politicians that are sympathetic to our cause, and not be bashful when asking for their assistance with important issues.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Remember that politicians respond to input from their constituents—and particularly issues related to impediments to access to care that affect voters. Politicians are most interested in two things—getting elected and staying in office. Physicians come into contact with hundreds of voters each week—our patients! Many current issues we are facing today directly impact our patients, and their future access to care. We are in a position to educate them regarding these important issues, and they, in turn, can raise their voice to their local congressmen and senators.

Dr. Saxe is president of the Florida Society of Rheumatology; senior partner in Arthritis Associates of South Florida; and medical director of Delray Research Associates in Delray Beach, Fla.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Page: 1 2 | Single Page
Share: 

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:Healthcare ReformImmune Systemrheumatologist

Related Articles

    Florida Law Puts Drug Pricing by Pharmacy Benefit Managers Under a Microscope Once Again

    August 8, 2022

    As of July 1, a Florida bill increases oversight of pharmacy benefit managers and offers some protection for pharmacies. However, the legislation has limited effects on patients and providers, highlighting the need for additional reform.

    Rheumatologists Air Frustrations with Pharmacy Benefit Managers at Annual Meeting

    January 19, 2018

    SAN DIEGO—Pharmacy benefit managers (PBMs) and their impact on drug prices and access to high-cost medications by the patients rheumatologists treat was a major theme at the 2017 ACR/ARHP Annual Meeting Nov. 3–8. In one session, industry experts tried to clarify the role for prior authorizations and drug formulary policies and explored ways to constructively…

    High Cost of Specialty Drugs Demands Action

    July 6, 2021

    Amid rising drug costs and the growing influence of pharmacy benefit managers on patient care decisions, physicians are increasingly called upon to advocate for affordable, evidence-based treatments for their patients.

    The Birth and Growth of Biotechnology, and the Impact of Biologic Drugs on Rheumatology

    June 15, 2017

    Here’s a trivia question: Where were the big ideas for the field of biotechnology first discussed? Answer: At a since-demolished delicatessen in Waikiki Beach, Hawaii. Go figure. The year was 1972, and Stanley Cohen, MD, professor of medicine at Stanford University in Palo Alto, Calif., and Herbert Boyer, PhD, a former professor and biochemist at the…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences